Navigation Links
Eurand Announces Positive Phase III Clinical Study Results

Company's Pancreatic Enzyme Replacement Therapy Significantly Improved Absorption of Fat and Protein during Clinical Trials

MILAN, Italy and DAYTON, Ohio, April 04, 2007 /PRNewswire/ -- Eurand, a global specialty pharmaceutical company, today unveiled data from two phase III clinical trials on its lead product candidate, Zentase(TM), formerly EUR-1008, for the treatment of Exocrine Pancreatic Insufficiency (EPI). The US Food and Drug Administration (FDA) granted fast track status for Zentase for the treatment of EPI. The company intends to file for FDA approval during the second quarter of 2007 for this potentially first-in-class pancreatic enzyme replacement therapy.

Zentase is a zero-overfill, highly-stable, porcine-derived pancreatic enzyme replacement therapy used to treat EPI and was designed to meet FDA guidelines for pancreatic enzyme replacement products(1). According to the FDA, no currently marketed pancreatic enzyme product (PEP) has been shown to demonstrate consistent enzyme bioactivity that results in predictable safety and effectiveness(2). Many of the current enzyme products contain overfill to compensate for product instability during shelf life, which can lead to variability in dosing. As a highly-stable product, Zentase does not require overfill. Currently, there are no FDA approved PEPs for the treatment of EPI on the market in the US.

"We are excited to present the results of our phase III studies supporting Zentase for the full spectrum of cystic fibrosis patients suffering from EPI, including those needing limited supplementation to those with very aggressive enzyme deficiency," said Gearoid Faherty, Eurand Chairman and CEO.

Zentase met all primary and secondary endpoints in two phase III clinical trials. The studies were designed to determine whether the product candidate could alleviate serious malabsorption associated with EPI in both a pediatric (younger than 7 ye
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand to Present Zentase Phase III Data
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Eurand Announces Positive Phase III Clinical Study Results
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
(Date:7/11/2014)... MELBOURNE, Australia , July 11, 2014  Australian ... today announced that it has raised A$19.3 million via ... Europe , the U.S., ... and A$3 million from a share purchase plan (SPP) ... A$16.3 million will be made in two tranches. ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... A. Grant, MD,Retina Macular Care, presented the ... that was designed to evaluate the adjuvant,use ... Lucentis(R),(ranibizumab) treatment of choroidal neovascularization secondary to,age-related ... presentation at,the 2008 Annual Meeting of the ...
... C Therapies Provides ... Clinical Practice, MILAN, Italy, April 26 Final ... study comparing the,leading therapies for chronic hepatitis C, were ... Association for the Study of the Liver,(EASL), providing important ...
Cached Medicine Technology:Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
(Date:7/11/2014)... London, UK (PRWEB) July 11, 2014 ... segment of the in-vitro diagnostics industry, which is expected ... next ten years. The sector owes its growth to ... threat to people’s health worldwide and a major factor ... diagnostic technologies, threat of bio-terrorism, and a broader availability ...
(Date:7/11/2014)... Utilizing the Keller Funnel, Quatela Center for ... a record number of complication-free breast augmentations. Far ... procedures without the occurrence of a capsular contraction. ... country for his expertise with the breast augmentation procedure. ... foundation for numerous studies and research. Most recently, ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is ... Concord Pavilion . When it comes to the summer concert ... The 37-year-old Georgia native is one of the biggest names in ... business. Bryan is currently out on his “That’s My Kind of ... stops the tour will be making through the rest of the ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
(Date:7/11/2014)... kind has found that organic foods and crops ... counterparts, including more antioxidants and fewer, less frequent ... unprecedented 343 peer-reviewed publications comparing the nutritional quality ... including fruits, vegetables, and grains. The study team ... organic and non-organic foods. , "Science marches ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... Kathleen Doheny HealthDay Reporter , THURSDAY, Oct. 7 ... cancer who have dense breasts may be at higher risk ... breast, a new study indicates. "The risk appears to ... that originally had the cancer," said Laurel A. Habel, a ...
... (Oct. 7, 2010)In 2006, Dr. Shimya Yaminaka of Kyoto ... medicine research world on fire when he successfully transformed ... behave like embryonic stem cells. Embryonic stem cells, the ... the ability to differentiate into any type of tissue. ...
... which participants are randomly assigned to different treatments by ... correctly, it,s widely accepted by the research community that ... But researchers at the University of Michigan ... medical devices to patients by investigating the impact of ...
... HealthDay Reporter , WEDNESDAY, Oct. 6 (HealthDay News) ... be taken with the blood thinner Plavix, a new ... medications, called PPIs, might interfere with the ability of ... reassuring data that there is not any clinically significant ...
... perhaps more than anyone realizes -- in basic biological ... reducing cancer risks, according to University of Oregon researchers. ... zebrafish, scientists in the UO Institute of Molecular Biology ... in the sterile environment of its eggshell through the ...
... friends and family members of mood history and symptoms ... research published online by the journal International Psychogeriatrics ... who is highly outgoing and fun-loving and who is ... miss the signs that indicate the person is depressed. ...
Cached Medicine News:Health News:Denser Breasts Raise Odds of Second Breast Cancer, Study Finds 2Health News:Denser Breasts Raise Odds of Second Breast Cancer, Study Finds 3Health News:Colorado researcher discovers mechanism for changing adult cells into stem-like cells 2Health News:U-M receives NIH, FDA grant to study adaptive clinical trial designs 2Health News:Heartburn Drugs, Plavix Seem Safe to Take Together 2Health News:Heartburn Drugs, Plavix Seem Safe to Take Together 3Health News:Gut microbes promote cell turnover by a well-known pathway 2Health News:Patient personality hinders detection of depression 2